glp 1 agonist statpearls Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective Advances in GLP-1 receptor agonists
Description
This class has gained popularity and attention in recent years due to its potential to combat obesity
Both Eli Lilly and Novo Nordisk have publicly acknowledged backorders and rationing of products like Mounjaro and Ozempic due to unprecedented demand
Within these classes, there are 6 FDA-approved weight loss medications: liraglutide, semaglutide, tirzepatide, orlistat, naltrexone/bupropion, and phentermine/topiramate
Circulation (2011) 124(21):233849
Another important factor reinforcing the segment's dominance is doctors' confidence in GLP-1 treatments for the treatment of diabetes
